Moderna (MRNA) Competitors

Takeda Pharmaceutical (NYSE:TAK) and Moderna (NASDAQ:MRNA) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

Does the MarketBeat Community prefer TAK or MRNA?

Moderna received 115 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. However, 56.82% of users gave Takeda Pharmaceutical an outperform vote while only 54.43% of users gave Moderna an outperform vote.

Company	Underperform	Outperform
Takeda Pharmaceutical	Outperform Votes 100 56.82%	Underperform Votes 76 43.18%
Moderna	Outperform Votes 215 54.43%	Underperform Votes 180 45.57%

Which has more risk & volatility, TAK or MRNA?

Takeda Pharmaceutical has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500. Comparatively, Moderna has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.

Is TAK or MRNA more profitable?

Takeda Pharmaceutical has a net margin of 4.53% compared to Moderna's net margin of -110.04%. Takeda Pharmaceutical's return on equity of 9.39% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.53%	9.39%	4.53%
Moderna	-110.04%	-28.74%	-21.83%

Do analysts rate TAK or MRNA?

Moderna has a consensus target price of $60.63, indicating a potential upside of 79.76%. Given Moderna's stronger consensus rating and higher possible upside, analysts clearly believe Moderna is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Moderna	4 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.04

Which has preferable earnings and valuation, TAK or MRNA?

Takeda Pharmaceutical has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.20B	1.56	$994.06M	$0.40	34.64
Moderna	$3.24B	4.01	-$3.56B	-$9.28	-3.63

Do institutionals & insiders believe in TAK or MRNA?

9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by company insiders. Comparatively, 15.7% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Does the media favor TAK or MRNA?

In the previous week, Moderna had 44 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 49 mentions for Moderna and 5 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.26 beat Moderna's score of 0.18 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	16 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	8 Negative mention(s)	3 Very Negative mention(s)	Neutral

Summary

Moderna beats Takeda Pharmaceutical on 10 of the 18 factors compared between the two stocks.